IDEAYA Biosciences, Inc. Earnings Per Share (Diluted)
IDEAYA Biosciences, Inc. (IDYA) reported Earnings Per Share (Diluted) of -$1.22 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-04
- IDEAYA Biosciences, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.22.
- IDEAYA Biosciences, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$1.11.
- IDEAYA Biosciences, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.94.
- IDEAYA Biosciences, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $1.33.
- IDEAYA Biosciences, Inc. earnings per share, diluted for fiscal 2025 was -$1.28.
- IDEAYA Biosciences, Inc. earnings per share, diluted for fiscal 2024 was -$3.36.
- IDEAYA Biosciences, Inc. earnings per share, diluted for fiscal 2023 was -$1.96.
- IDEAYA Biosciences, Inc. earnings per share, diluted for fiscal 2022 was -$1.42.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.22 10-Q · filed 2026-08-04 | -$2.33 10-Q · filed 2026-08-04 | -$3.28 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.95 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2026-03-31 | -$1.11 10-Q · filed 2026-05-05 | -$2.05 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-12-31 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-29 | $0.40 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.28 10-K · filed 2026-02-17 |
| 2025-09-30 | $1.33 10-Q · filed 2025-11-04 | $0.47 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$0.34 10-Q · filed 2025-11-04 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-06-30 | -$0.88 10-Q · filed 2026-08-04 | -$1.69 10-Q · filed 2026-08-04 | -$3.18 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.79 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-03-31 | -$0.82 10-Q · filed 2026-05-05 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.91 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$3.61 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2024-12-31 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$2.10 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$2.80 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$3.36 10-K · filed 2026-02-17 |
| 2024-09-30 | -$0.60 10-Q · filed 2025-11-04 | -$1.27 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$1.81 10-Q · filed 2025-11-04 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2024-06-30 | -$0.68 10-Q · filed 2025-08-05 | -$1.21 10-Q · filed 2025-08-05 | -$1.73 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$2.21 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2024-03-31 | -$0.53 10-Q · filed 2025-05-06 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.51 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2023-12-31 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.48 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.96 10-K · filed 2026-02-17 |
| 2023-09-30 | -$0.46 10-Q · filed 2024-11-04 | -$0.95 derived: net income ÷ weighted average shares · filed 2024-11-04 | -$1.44 10-Q · filed 2024-11-04 | -$1.94 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2023-06-30 | -$0.50 10-Q · filed 2024-08-06 | -$0.99 10-Q · filed 2024-08-06 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.53 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2023-03-31 | -$0.49 10-Q · filed 2024-05-07 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2022-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.42 10-K · filed 2025-02-18 |
| 2022-09-30 | $0.04 10-Q · filed 2023-11-07 | -$0.51 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.88 10-Q · filed 2023-11-07 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2022-06-30 | -$0.57 10-Q · filed 2023-08-10 | -$0.93 10-Q · filed 2023-08-10 | -$1.41 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.72 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2022-03-31 | -$0.36 10-Q · filed 2023-05-09 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.48 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2021-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.41 10-K · filed 2024-02-20 |
| 2021-09-30 | -$0.31 10-Q · filed 2022-11-08 | -$0.64 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$0.92 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$0.33 10-Q · filed 2022-08-15 | -$0.62 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | -$1.40 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |